Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zn-Telomir · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Phase I Dose Escalation | EXPERIMENTAL | Participants receive oral Zn-Telomir once daily on Days 1-14 of each 28-day cycle at assigned cohort dose levels of 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 400 mg. Number of cycles will vary based on dose level and tolerability. |
| Phase II Dose Expansion | EXPERIMENTAL | Participants receive oral Zn-Telomir at the recommended Phase II dose once daily on Days 1-14 of each 28-day cycle for up to 4 cycles, if tolerated. |
| Name | Type | Description |
|---|---|---|
| Zn-Telomir | DRUG | Zn-Telomir is an oral small molecule that inhibits iron-dependent KDM enzymes, reduces tumor DNA methylation, and kills cancer cells in an iron-dependent manner - targeting epigenetic and metal homeostasis drivers of cancer cell survival. |
Inclusion Criteria: 1. Clinically defined histologically or cytologically confirmed triple-negative breast cancer (TNBC) 2. Locally advanced unresectable or metastatic disease 3. Must have completed prior anticancer therapy discontinued for a least 28 days 4. Disease progression after prior systemi...